Prognostic factors for patients with relapsed central nervous system nongerminomatous germ cell tumors.

Pediatr Blood Cancer

The Division of Hematology, Oncology and BMT, The Department of Pediatrics, Nationwide Children's Hospital, The Ohio State University, Columbus, Ohio.

Published: January 2022

We aimed toidentify prognostic factors that may help better understand the behavior of relapsed central nervous system nongerminomatous germ cell tumors. We identified nine studies, including 101 patients; 33 patients (33%) were alive 12 months post-initial relapse. Sixty percent of patients with serum/cerebrospinal fluid (CSF) alpha-fetoprotein (AFP) level ≤25 ng/mL at initial diagnosis were survivors compared with 28% among patients with serum/CSF AFP level >25 ng/mL (P = 0.01). Seventy-one percent of patients who achieved complete response/continued complete response (CR/CCR) by the end of therapy at relapse were survivors compared with 7% among patients who had less than CR/CCR (P < 0.0001). Forty-eight percent of patients who received marrow-ablative chemotherapy followed by autologous hematopoietic cell rescue (HDCx/AuHCR) following relapse were survivors compared with 12% among patients who did not receive HDCx/AuHCR (P = 0.0001). Local relapse site, gross total surgical resection, and radiotherapy at relapse were not associated with improved outcomes.

Download full-text PDF

Source
http://dx.doi.org/10.1002/pbc.29365DOI Listing

Publication Analysis

Top Keywords

percent patients
12
survivors compared
12
patients
9
prognostic factors
8
relapsed central
8
central nervous
8
nervous system
8
system nongerminomatous
8
nongerminomatous germ
8
germ cell
8

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!